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Abstract
Pressure ulcer incidence is high in intensive care units. This causes a serious
financial burden to healthcare systems. We evaluated the cost-effectiveness of
multi-layered silicone foam dressings for prevention of sacral and heel pres-
sure ulcers in addition to standard prevention in high-risk intensive care
units patients. A randomised controlled trial to assess the efficacy of multi-lay-
ered silicone foam dressings to prevent the development of pressure ulcers on
heels and sacrum among 422 intensive care unit patients was conducted.
Direct costs for preventive dressings in the intervention group and costs for
treatment of incident pressure ulcers in both groups were measured using a
bottom-up approach. A cost-effectiveness analysis by calculating the incremen-
tal cost-effectiveness ratio using different assumptions was performed. Addi-
tional dressing and labour costs of €150.81 (€116.45 heels; €34.36 sacrum) per
patient occurred in the intervention group. Treatment costs were €569.49 in
the control group and €134.88 in the intervention group. The incremental cost-
effectiveness ratio was €1945.30 per PU avoided (€8144.72 on heels; €701.54
sacrum) in the intervention group. We conclude that application of preventive
dressings is cost-effective for the sacral area, but only marginal on heels for
critically ill patients.
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1 | INTRODUCTION
Pressure ulcers (PUs) are defined as areas of localised
injuries to the skin and/or underlying tissues, usually
over bony prominences, as a result of persistent local
pressure or pressure in combination with shear forces.1
Hospital-acquired pressure ulcers (HAPUs) are associated
with serious consequences including medical complica-
tions, prolonged hospital stays and death.2 Especially crit-
ical ill patients in intensive care units (ICUs) are at high
risk of developing HAPUs. This can be explained by their
underlying multiple comorbidities, unstable hemody-
namics, immobility and increased use of special medica-
tions.3 Therefore, in this high-risk setting the PU
incidence and prevalence are particularly high.4-6 PUs
are considered mostly preventable and are widely used as
an indicator of the quality of nursing in hospital care.7
Besides their substantial impact on the patient's well-
being with regard to physical, social as well as psycholog-
ical aspects, PUs cause a serious financial burden for all
involved parties.8,9 The costs of prevention and treatment
of PUs were recently summarised by Demarré and col-
leagues. Reported costs of prevention ranged from €2.65
to €87.57 per patient per day and the costs of treatment
ranged from €1.71 to €470.49 per patient per day across
different care settings.9 A recent article reported average
direct treatment costs of USD 12 for category I PUs to
USD 66 834 for category IV PUs in ICU patients.10
Another recent article suggests that a HAPU could cost
USD 10 708 per patient on average.11 These findings pro-
vide clear justification for the value of prevention. Previ-
ous research specifically on the economics of preventing
PUs has illustrated that a standard prevention protocol is
not only cost-effective, but may be cost saving across
multiple care settings including intensive care.12,13
Recent studies have also found that including prophylac-
tic dressings in a prevention protocol provides added
value.14,15
Regular repositioning, early mobilisation and the use
of pressure redistributing support surfaces are corner-
stones of PU prevention.1 There is emerging evidence
that the application of preventive dressings to PU predi-
lection sites in addition to standard prevention helps to
prevent the development of PUs in ICU patients16-21 and
patients on other wards assessed to be at “high” or “very
high risk” for developing PUs.22 From June 2015 to July
2018, a pragmatic randomised controlled trial (RCT) was
conducted at the Charité–Universitätsmedizin Berlin.
Results of this trial found an absolute risk reduction of
0.08 (95% confidence interval [CI] 0.03-0.13) and a rela-
tive risk reduction of 0.74 (95% CI 0.38-0.89) of category
II PUs and higher.23
The objective of this article is to evaluate the cost-
effectiveness of using multi-layered silicone foam dress-
ings for PU prevention based on this RCT. We hypothe-
sized that prophylactic dressings would be cost-effective
on both sacrum and heels in intensive care.
2 | MATERIALS AND METHODS
A cost-effectiveness analysis based on the pragmatic
RCT23 was conducted from the hospital perspective. The
time horizon of the analysis was based on the average
duration of patient admission to an ICU. An incremental
cost-effectiveness ratio (ICER) was calculated directly
from information in the trial, and expressed in terms of
cost per PU avoided; decision modelling was not needed.
Analytical uncertainty was quantified through univariate
sensitivity analysis.
2.1 | Design
A randomised, controlled, two arms, superiority pragmatic
trial was performed with a 1:1 allocation to the interven-
tion or control group. Patients in both groups received the
hospital PU prevention standard care including PU risk
Key Messages
• Pressure ulcer incidence in intensive care units
is high und causes a serious financial burden
to healthcare systems
• There is little knowledge about the cost-effec-
tiveness of multi-layered silicone foam dress-
ings for pressure ulcer prevention in intensive
care unit patients
• A randomised controlled trial among 422 inten-
sive care unit patients was performed to assess
the efficacy of multi-layered silicone foam
dressings for prevention of pressure ulcers on
heels and sacrum
• The application of the dressings to sacrum and
heels, in addition to standard preventive mea-
sures, reduced the pressure ulcer incidence in
these high-risk patients
• Applying preventive dressings on the sacral
area in addition to standard pressure ulcer pre-
vention in high-risk intensive care unit patients
is clinically effective and cost-effective
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assessment, skin inspection within 6 hours after admission
and, depending on the respective risk categories, the imple-
mentation of preventive measures, including (a) patient
information, (b) daily skin inspection, (c) mobilisation,
(d) use of special support surfaces, (e) repositioning and (f)
floating heels.24 Patients assigned to the intervention group
additionally had a multi-layered silicone foam dressing
applied to both heels (Mepilex Border Heel, Mölnlycke
Health Care, Sweden) and to the sacrum (Mepilex Border
Sacrum, Mölnlycke Health Care, Sweden).
All included patients were followed up at least once
daily in the ICU by members of the study team to ensure
compliance, doing skin inspections, documenting health
conditions and assessing the PU risk and to verify if any
new PU had developed. In the intervention group, addi-
tional attention was paid to the correct application and
fit of the dressings and that no other skin care products
were used between the skin and the dressings. The daily
skin assessment in the intervention group was performed
by partially peeling off the dressings to visualise the
underlying skin, afterwards the dressing was reapplied.
The dressings were changed regularly every 3 days and
additionally in case of becoming soiled or dislodged.
Any newly developed PU on heels or sacral area that
had occurred during the study was documented and
followed up daily during the remaining study period,
including used resources (consumable resources and
labour costs) for PU treatment.
2.2 | Study population
To be considered eligible for study participation, potential
participants had to be older than 18 years, at high or very
high PU risk according to the hospital PU prevention
standard24 and had to have an expected length of stay of
at least 3 days. The assessment of high or very high PU
risk of the ICU patient was assessed by the study person-
nel according to the classification of the hospital PU pre-
vention standard.24 Participants were included in the
trial within a maximum of 6 hours after admission to a
surgical or internal ICU. Patients at the end of life, with
existing PUs or trauma at the heels and sacrum or known
allergies to the used dressings were excluded. ICU
patients positioned on air-fluidised beds and patients
who could not be repositioned due to medical reasons
were not included.
2.3 | Outcome measures
The primary outcome was the cumulative incidence of
PUs of category II, III, IV, unstageable and deep tissue
injury (DTI) at heels or sacrum developed in the ICU in
both groups. PUs were categorised according to the
NPUAP/EPUAP 2014 classification system.4
2.4 | Resources and costs
A bottom-up approach was used to calculate the costs of
prevention and treatment of PUs by documenting the
actual use of resources during the trial. Resources for the
calculation of costs included preventive dressings, nurs-
ing time (wound assessment, documentation, wound
care, preventive dressing application/change), dressings
for wound care in case of newly developed PUs on heels
and/or sacrum, consultation by wound managers (WMs)
and medical consumables (eg, gloves, cotton gaze). The
costs of these resources were considered only for the time
of ICU stay and after the transfer to peripheral wards
within the hospital. Further treatment costs associated
with the PUs after the patients had been discharged from
the hospital were not included in the analysis.
Costs for the standard PU prevention care were not
listed separately because this was provided in both
groups equally, so we assume that the costs for the stan-
dard care were similar in both groups.
2.5 | Costs for prevention
Calculated costs of PU prevention in the intervention
group were based on the sum of the costs for the applied
preventive dressings and labour costs for application or
change. Therefore, we counted the actual number of used
dressings on heels and sacrum and multiplied the num-
ber by the unit price of the dressings. Labour costs were
calculated by multiplying the time needed for the appli-
cation or change of the dressings by the hourly pay rate
of the nurses. In Germany, the hourly pay rate for regis-
tered nurses (RN) with a collective labour agreement in
public services varies according to their years of profes-
sional experience. Experience-dependent payment ranges
from 1 to 15 years. We used for our analysis the hourly
pay rate of a RN with 6 to 9 years of work experience in
the federal state of Berlin, Germany. We used the average
prices for dressing materials and hourly pay rates for
nurses from June 2015 to July 2018.
2.6 | Costs for PU treatment
The cost associated with newly developed PUs on heels
and sacrum is the sum of multiplying the resources for
PU treatment by their respective unit prices and by
EL GENEDY ET AL. 1293
multiplying the needed labour time for wound care,
wound assessments and documentation and external
WM consultation by the hourly pay rate of RNs or WMs.
2.7 | ICER analysis
We performed a cost-effectiveness analysis by calculating
the ICER. ICERs express how much more than an exis-
ting treatment a new more effective treatment would cost
for additional benefits.25 In general, a higher value of the
ICER indicates a less cost-effective treatment. The ICER
was measured in terms of cost spent on inpatient care
and prevention materials relative to the PU incidence on
a per patient basis using the following formula:
The ICER is expressed in Euros (€) per PU avoided
per patient.
2.8 | Sensitivity analysis
To explore the uncertainty of our cost estimates and to
identify the impact of key variables on the cost-effec-
tiveness, we performed multiple univariate sensitivity
analyses. This was performed by varying the number of
used preventive dressings, the price of the dressings,
the nursing time needed for dressing application or
changes as well as the average costs for intervention.
Variables included in the analysis range between ±15%
and results were presented in tornado diagrams. In
addition, we also varied the effects of the intervention
to explore the resulting costs. For this purpose, we var-
ied the incidence of PUs in the intervention group also
within a range of ±15%. The described analyses were
applied to the entirety of used resources and costs as
well as in two separate analyses for sacrum and heel
dressings.
3 | RESULTS
3.1 | Baseline data
In total, 422 ICU patients were analysed. Except
for a slight difference regarding the distribution of
sex, the intervention and control group were com-
parable with regard to mean age and proportions of
patients with high and very high PU risk at
baseline.
3.2 | Resources and costs for PU
prevention
Applied additional resources and assigned costs are
shown in Table 1. In total, 1050 sacral and 2260 heel
dressings were used. The total material costs for the used
dressings were €28 463.82 (heel dressings: €22 292.52;
sacrum dressings: €6171.13). Based on our own estima-
tion and published data26 we assumed that the time per
dressing application or change was 2 minutes when the
patient was turned over and held by nurses as part of reg-
ular repositioning, skin inspections or other medical
examinations. The total labour costs for application or
change were €3508.60 (heel dressings: €2395.60; sacrum
dressings: €1113.00). Thus, the total additional direct
costs of PU prevention in the intervention group were
€31 972.42 with an average cost of €150.81 per patient
(Table 1).
3.3 | Resources and costs of PU
treatment
The resources and direct treatment costs for PUs that had
developed within the trial are shown in Table 2. These
costs were categorised into material costs (dressings,
gloves and further medical consumables) and labour
costs (external wound consultations, wound assessment
and documentation, wound care).
The total costs for PU treatment in the intervention
group (n = 6 PUs) were €134.88 (€106.77 material; €28.11
labour costs) with an average cost of €22.48 per patient.
In the control group (n = 22 PUs) the total costs for treat-
ment were €569.49 (€445.96 material; €123.53 labour
costs) with an average of €25.89 per patient. The total
direct treatment costs in the control group were 4.2 times
higher than in the intervention group, and the average
treatment costs per PU case were €3.41 higher in the con-
trol group.
ICER=
Costs intervention groupper patient−Costs control groupper patient
Pressure ulcer incidence intervention group−Pressure ulcer incidence control group
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Table 3 shows the treatment costs for different PUs
per day and per PU case according to their location and
category. The daily treatment costs range from €0.33
(heel; category II) to €4.32 (sacrum; category III).
Based on our study documentation we calculated an
average length of stay in the hospital after PU develop-
ment of 12 days. Based on this duration we calculated the
costs per PU case.
The primary outcome analysis showed that the
cumulative incidence of PU categories II to DTI was
6.6% (28/422). 10.5% (22/210) of the patients in the
control group developed a PU of the category II to
DTI on heels or sacrum compared with 2.8% of
patients (6/212) in the intervention group (P = .001)
(Table 4).
3.4 | Base case
In the base case, the ICER for additional preventive
dressings compared with hospital PU standard care alone
was €1945.30 per PU avoided (Figure 1A). The analysis of
TABLE 1 Additional resources and direct costs of prevention in the intervention group
Intervention group (n = 212)
Unit Number Unit price (€) Subtotal (€)
Sacral dressing 18 × 18a 1017 5.81 5912.52
Sacral dressing 23 × 23a 33 7.84 258.78
Heel dressinga 2260 9.86 22 292.52
Nursing time sacral dressingb (2 min per
change)
1050 1.06 1113.00
Nursing time heel dressingb (2 min per change) 2260 1.06 2395.60
Total €31 972.42
aUnit price obtained from Mölnlycke Healthcare AB.
bUnit price obtained from personnel department of Charité – Universitätsmedizin Berlin. €31.83 were the average employers' costs (2015–
2018) per hour for a registered nurse in an intensive care unit with 6 to 9 years of nursing experience.
TABLE 2 The total direct costs of pressure ulcer (PU) treatment in the intervention and control group










External wound consultationa (5 min) — — — 5 2.64 13.19
Wound assessment/documentationb
(2 min)
7 1.06 7.43 23 1.06 24.40
Wound careb (3 min) 13 1.59 20.69 54 1.59 85.93
Foam dressingsc 13 7.00 91.00 46 7.00 322.02
Hydrocolloid dressingsc — — — 7 6.99 48.96
Absorbent dressingsc — — — 1 5.85 5.85
Skin protectantc 2 2.16 4.32 10 2.16 21.62
Sodium chloride irrigationc 13 0.26 3.38 54 0.26 14.04
Glovesc 52 0.03 1.56 216 0.03 6.48
Other materialsc 13 0.50 6.50 54 0.50 27.00
Total direct costs for PU treatment per
group
€134.88 €569.49
aUnit price obtained from personnel department of Charité – Universitätsmedizin Berlin. €31.66 were the average employers' costs (2015-
2018) per hour for a registered nurse (wound care manager) with 6 to 9 years of nursing experience.
bUnit price obtained from personnel department of Charité – Universitätsmedizin Berlin. €31.83 were the average employers' costs (2015-
2018) per hour for a registered nurse in an intensive care unit with 6 to 9 years of nursing experience.
cUnit price obtained from the hospital purchase department of Charité – Universitätsmedizin Berlin.
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the ICERs for preventive dressings separated by heels
and sacrum show a base case ICER of €8144.72 per heel
(Figure 1B) and €701.54 per sacrum (Figure 1C) PU
avoided.
3.5 | Sensitivity analysis
Results of the sensitivity analyses are shown in tornado
diagrams (Figure 1). We identified the dressing costs in
general and the number of used heel dressings as the
parameters that mostly influenced the ICER. Compared
with these findings the variation of nursing time had a
noticeably weaker impact on the results. Variation of
the incidence in the intervention group by ±15% also
showed that the incidence has a higher impact on the
ICER than the nursing time and number of used
sacrum dressings but has lesser impact than the dress-
ing costs and number of used heel dressings
(Figure 1A).
4 | DISCUSSION
Based on the results of a pragmatic RCT this economic
analysis indicates that approximately €2000 are needed to
prevent one sacral and/or heel PU category II or higher
in high-risk ICU patients. Compared with other costs this
might be considered as a good value from the patient and
health system perspective. From the hospital perspective,
this might be considered expensive. However, the ICER
was substantially lower for preventing sacral PUs com-
pared with heel PUs. The main reason was that only few
heel PUs developed but a high number of sacral PUs in
the underlying RCT. The ICER might be completely dif-
ferent in a setting where more heel PUs occur.
Compared with other expensive preventive measures
an ICER of approximately €700 for preventing one sacral
PU category II or higher can be considered good. Because
incident PUs and associated costs were only documented
for the length of stay on the ICU and the within hospital
stay, the actual treatment costs are higher. Direct and
TABLE 3 Treatment costs per day
per pressure ulcer (PU) case by
category, localisation and group
Intervention Control
Sacrum (€) Heel Sacrum (€) Heel (€)
Category II
Cost per day 2.97 — 3.34 0.33
Cost per hospital PU casea 35.69 — 40.08 3.95
Category III
Cost per day — — 4.32 —
Cost per hospital PU casea — — 51.80 —
DTI
Cost per day 1.06 — 1.44 0.66
Cost per hospital PU casea 12.73 — 17.30 7.90
Average treatment cost per PU per day 1.93 — 3.03 0.50
Average treatment cost per PU casea 24.21 — 36.39 5.93
Abbreviation: DTI, deep tissue injury.
aCosts per hospital PU case are based on the calculated average stay in the hospital of 12 days
after the development of a PU in an intensive care unit.
TABLE 4 Numbers of incident
pressure ulcers (PUs) in the
intervention and control groups by
category and localization
Intervention (n = 6) Control (n = 28)
Category Sacral Heel right Heel left Sacral Heel right Heel left
I — — — 4 1 1
II 4 — — 10 1 1
III — — — 1 — —
IV — — — — — —
DTI 2 — — 8 — 1
Abbreviation: DTI, deep tissue injury.
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indirect costs including rehabilitation services, wound
care in the community or the loss of productivity after
hospital discharge were not considered in this analysis.
Results further indicate that the main costs were due to
the preventive dressings. Therefore, prolonging the wear
times might be one strategy to improve the cost-effective-
ness from the hospital perspective.
There is clear evidence that the additional application
of preventive dressings to the sacral area and heels of
ICU patients reduces the development of new PUs at
these areas.17,19,23,27 There is a lack of economic evalua-
tions to assess the cost-effectiveness of these dressings in
comparison to standard care alone. A cost-benefit analy-
sis of an RCT with a similar setting showed that the use
of preventive dressings results in cost savings in the acute
care hospital.26
To the best of our knowledge, there is no economic
analysis that investigates the cost-effectiveness of preven-
tive dressings for prevention of sacral and heel PUs in
addition to standard prevention in high-risk ICU patients
by calculating ICERs.
It is also important to keep in mind that single inter-
ventions such as the use of preventive dressings is only
one part in the complex process of PU prevention. Other
important aspects are PU risk determination and early
PU detection to allocate preventive interventions.1
Improved risk assessment strategies combined with
targeted preventive intervention might further increase
cost-effectiveness but currently the link between risk
assessment, intervention planning and conduct in clinical
practice is weak.28-30
5 | LIMITATIONS
The follow-up visits stopped when patients were dis-
charged from the hospital. For that reason, we could not
measure the duration until complete healing. The major-
ity of incident PUs within this study did not heal during
the hospital stay. Therefore, additional costs following
the patients' discharge from hospital were not taken into
account but would significantly increase the total costs of
PU treatment thus reducing the ICER. Furthermore, the
study population consisted mostly of critically ill patients
or patients with major trauma, therefore some of these
patients died soon after the development of a PU owing
to their underlying illness. These circumstances make it
difficult to calculate the time until the healing of a
PU. For these reasons, we focused only on the costs dur-
ing the hospital stay and not until PU healing.
Even though we meticulously collected data for PU
treatment, it is likely that we missed resources and/or
underestimated costs. However, results of the sensitivity
analyses indicate that the variation of our estimates is
minor. This economic analysis is based on a pragmatic
RCT that might be considered as an optimal approach
for an economic analysis. We could also show that the
included sample was representative for a high-risk ICU
FIGURE 1 Incremental cost-effectiveness ratio (ICER) tornado diagram of multiple univariate sensitivity analysis. The influence of
each variable on the ICER is presented from top to bottom. A, ICERs for additional use of heel and sacrum dressings. B, ICERs for
additional use of heel dressings only. C, ICERs for additional use of sacrum dressings only
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population.23 However, the observed effect sizes and
consequently the ICERs might not be comparable to
other ICUs.
In this study, we used a bottom-up trial-based
approach to calculate resources and costs. Other health
economic evaluation approaches are model-based (eg,
Markov-models) or hybrids between trials-based and
modelling techniques.31 Every approach has advantages
and disadvantages.32
6 | CONCLUSION
Applying preventive dressings on the sacral area in addi-
tion to standard PU prevention in high-risk ICU patients
is clinically effective and cost-effective. Due to the low
incidence of heel PUs, the application of preventive
dressings on the heels was much more expensive and less
cost-effective. Preventive dressings do not replace
established measures but rather represent an effective
addition for PU prevention. In terms of economic effi-
ciency, only high-risk patients should receive additional
preventive dressings.
This cost-effectiveness analysis was conducted from
the hospital perspective. Nevertheless, the totality of all
the affected parties should be considered, whether in
financial or social terms. Therefore, further research is
needed to determine the far-reaching consequences of
PUs for the patient as well as the community.
Future PU prevention studies should combine differ-
ent complementary preventive approaches to assess the
effectiveness and costs of the total complex care process.
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